The under-recognized role of dopamine in the treatment of major depressive disorder.

Abstract:

:Major depressive disorder (MDD) is currently the second most common cause of disability worldwide. Current treatment of MDD with selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors is limited by efficacy and tolerability issues, highlighting the unmet need in the treatment of patients with MDD. Deficiencies in dopamine, serotonin and noradrenaline are thought to underpin MDD pathophysiology. Atypical antipsychotics, which modulate these receptor systems, may provide additional treatment options. This article assesses the current treatment options available for patients with MDD and considers possible future therapies. The potential role of atypical antipsychotics such as olanzapine, risperidone and quetiapine in the treatment of MDD is explored based on evidence from bipolar depression trials and preliminary studies in patients with MDD.

authors

Montgomery SA

doi

10.1097/YIC.0b013e3282f2b3cb

subject

Has Abstract

pub_date

2008-03-01 00:00:00

pages

63-9

issue

2

eissn

0268-1315

issn

1473-5857

pii

00004850-200803000-00001

journal_volume

23

pub_type

杂志文章,评审
  • Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients.

    abstract::The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. Each patient received 3 mg risperidone twice a day for 28 days. Amitriptyline was coadministered at doses of 50 mg/d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199705000-00004

    authors: Sommers DK,Snyman JR,van Wyk M,Blom MW,Huang ML,Levron JC

    更新日期:1997-05-01 00:00:00

  • The effects of d- and l-fenfluramine (and their interactions with d-amphetamine) on cortisol secretion.

    abstract::Twelve normal weight healthy male volunteers participated in a double-blind, placebo-controlled trial of the effects of d- and l-fenfluramine, d-amphetamine, and the interactions between the two isomers of fenfluramine with amphetamine, on cortisol secretion. d-Fenfluramine and d-amphetamine in combination produced th...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300830-00001

    authors: Feeney S,Goodall E,Silverstone T

    更新日期:1993-10-01 00:00:00

  • An open-label study of escitalopram in body dysmorphic disorder.

    abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000194378.65460.ef

    authors: Phillips KA

    更新日期:2006-05-01 00:00:00

  • Somnambulistic-like behaviour in patients attending a lithium clinic.

    abstract::The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Landry P,Warnes H,Nielsen T,Montplaisir J

    更新日期:1999-05-01 00:00:00

  • Antidepressant-induced hypomania in obsessive-compulsive disorder.

    abstract::Out of ten consecutive patients with DSM-III-R obsessive-compulsive disorder without any previous history of bipolarity, three patients showed antidepressant-induced hypomania (clomipramine, one patient; fluvoxamine, two patients) within the first 5 to 8 weeks of the drug treatment. These data support the previous res...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199609000-00008

    authors: Rihmer Z,Barsi J,Belsõ N,Pestality P,György S

    更新日期:1996-09-01 00:00:00

  • Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?

    abstract::Treatment of psychotic symptoms with traditional neuroleptics has been complicated by acute extrapyramidal syndromes (EPS) and late occurring tardive dyskinesia. These widely prevalent disorders have both motor and mental components which impose additional impairments on patients who are already substantially limited ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199702001-00004

    authors: Casey DE

    更新日期:1997-02-01 00:00:00

  • Treatment of generalized anxiety disorder with citalopram.

    abstract::Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200205000-00002

    authors: Varia I,Rauscher F

    更新日期:2002-05-01 00:00:00

  • Comparison of performance of healthy volunteers given prazepam alone or combined with ethanol. Relation to drug plasma concentrations.

    abstract::The interaction between a single dose of 20 mg of prazepam and 0.5 g/kg body weight ethanol was investigated in 12 healthy male volunteers by nine objective performance tests, eight visual analogue self-rating scales and measurement of prazepam and ethanol plasma concentrations, using a double-blind three-way crossove...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199100640-00004

    authors: Girre C,Hirschhorn M,Bertaux L,Palombo S,Fournier PE

    更新日期:1991-01-01 00:00:00

  • Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.

    abstract::Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment. At follow-up most patients (74%) did not suffer from panic attacks at all. In the beginnin...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300820-00006

    authors: Lepola UM,Rimón RH,Riekkinen PJ

    更新日期:1993-07-01 00:00:00

  • Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia.

    abstract::Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investig...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199606003-00009

    authors: Liebowitz MR,Heimberg RG

    更新日期:1996-06-01 00:00:00

  • Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

    abstract::C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3283400cd3

    authors: Kim SH,Reaven G,Lindley S

    更新日期:2011-01-01 00:00:00

  • Toleration and safety of sertraline: experience worldwide.

    abstract::The clinical trial programme of sertraline, a selective serotonin re-uptake inhibitor, has shown the drug to have a favourable safety and toleration profile. In contrast, the tricyclic antidepressant, amitriptyline, produced a significant level of side effects, particularly anticholinergic. The side-effect profile of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199112002-00007

    authors: Doogan DP

    更新日期:1991-12-01 00:00:00

  • Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline.

    abstract::A total of 101 patients entered a double-blind, parallel-group study in general practice, comparing the efficacy and tolerability of paroxetine and amitriptyline in elderly depressed patients. All patients received placebo for 1 week followed by active therapy for a total of 6 weeks. Medication was randomly allocated,...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199206004-00009

    authors: Hutchinson DR,Tong S,Moon CA,Vince M,Clarke A

    更新日期:1992-06-01 00:00:00

  • Urinary hesitancy and retention caused by ziprasidone.

    abstract::We report the case of a patient with schizophrenia who developed urinary hesitancy and eventually urinary retention, 6 months after continuous treatment with ziprasidone; he had been administered no other medication during this time. The micturition difficulties resolved immediately upon discontinuation of ziprasidone...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000182117.49887.e7

    authors: Xomalis D,Bozikas VP,Garyfallos G,Nikolaidis N,Giouzepas J,Fokas K

    更新日期:2006-01-01 00:00:00

  • Benzodiazepine exposure in subjects with incident Alzheimer's disease and related syndromes in France: a longitudinal study 2011-2017.

    abstract::Benzodiazepines are commonly used for behavioral and psychiatric symptoms of dementia, despite their numerous adverse effects and the lack of evidence regarding their efficacy in this context. We studied longitudinal benzodiazepines exposure in incident cases of Alzheimer's disease and related syndromes (ADRS) in Fran...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000312

    authors: Poncet M,Gardette V,Couret A,Renoux A,Lapeyre-Mestre M,Gallini A

    更新日期:2020-09-01 00:00:00

  • Prediction of response to acute neuroleptic treatment in schizophrenia.

    abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199605002-00008

    authors: Gaebel W

    更新日期:1996-05-01 00:00:00

  • Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome.

    abstract::Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Horiguchi J,Yamashita H,Mizuno S,Kuramoto Y,Kagaya A,Yamawaki S,Inami Y

    更新日期:1999-01-01 00:00:00

  • The effects of methylamphetamine on mood and appetite in depressed patients: a placebo-controlled study.

    abstract::Methylamphetamine given intravenously as a single 15 mg dose led to a pronounced elevation of mood in 7 out of 21 depressed patients compared to a control injection of sterile water administered on another occasion in random order under double-blind conditions. All 7 responders experienced an increase of VAS self-rati...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198604000-00004

    authors: Cookson J,Silverstone T

    更新日期:1986-04-01 00:00:00

  • Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels.

    abstract::Lithium is widely used in the treatment of bipolar disorder. Here we describe the syndrome of irreversible lithium-effectuated neurotoxicity in a patient within therapeutic doses and levels, which persisted after discontinuation of Lithium. A 50-year-old gentleman with Bipolar disorder presented with symptoms of Mania...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000341

    authors: Jha A,Pai NM,Ganjekar S,Desai G,Chaturvedi SK

    更新日期:2021-03-01 00:00:00

  • A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group.

    abstract::Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-200015030-00001

    authors: Emsley RA,Raniwalla J,Bailey PJ,Jones AM

    更新日期:2000-05-01 00:00:00

  • Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.

    abstract::Sertindole is a novel atypical antipsychotic, which has shown efficacy in the treatment of positive and negative symptoms of schizophrenia in phase II and III studies. Furthermore, these studies have demonstrated tolerability and a favourable side-effect profile. In contrast to classical antipsychotics, sertindole was...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015040-00003

    authors: Pezawas L,Quiner S,Moertl D,Tauscher J,Barnas C,Küfferle B,Wolf R,Kasper S

    更新日期:2000-07-01 00:00:00

  • Carbamazepine in rapid cycling bipolar affective disorder.

    abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198804000-00003

    authors: Joyce PR

    更新日期:1988-04-01 00:00:00

  • Depression in the community: results of the first Italian survey.

    abstract::The 6-month prevalence of depression in the Italian community was evaluated by means of the modified-Mini-International-Neuropsychiatric Interview (MINI) administered with a computer-prompted interview to a representative panel of 3550 individuals. Major depression and minor depression accounted for 8.0% and 2.9% of t...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200101000-00006

    authors: Dubini A,Mannheimer R,Pancheri P

    更新日期:2001-01-01 00:00:00

  • The relationship between social phobia and avoidant personality disorder: workshop report 3.

    abstract::Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

    journal_title:International clinical psychopharmacology

    pub_type:

    doi:

    authors: Dahl AA

    更新日期:1996-06-01 00:00:00

  • An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

    abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0000000000000121

    authors: Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

    更新日期:2016-05-01 00:00:00

  • Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

    abstract::The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/00004850-200507000-00002

    authors: Gasquet I,Haro JM,Novick D,Edgell ET,Kennedy L,Lepine JP,SOHO Study Group.

    更新日期:2005-07-01 00:00:00

  • Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale.

    abstract::The aim was to evaluate the efficacy of venlafaxine extended release (ER) on characteristics of resilience, measured by the Connor-Davidson Resilience Scale, in patients with posttraumatic stress disorder (PTSD). Data were evaluated from a randomized, 6-month, international, multicenter study of adult outpatients with...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e32830c202d

    authors: Davidson J,Baldwin DS,Stein DJ,Pedersen R,Ahmed S,Musgnung J,Benattia I,Rothbaum BO

    更新日期:2008-09-01 00:00:00

  • Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study.

    abstract::Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000024

    authors: Xue Q,Xiong X,Feng Y,Yao L,Chen S,Xiang L

    更新日期:2014-09-01 00:00:00

  • Clinical trials of new antipsychotics: a critical appraisal.

    abstract::In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199903000-00012

    authors: Barbui C,Garattini S

    更新日期:1999-03-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00